(Reuters) – Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
In a note published by the European Medicines Agency (EMA) on Monday, the obesity drug maker recommended healthcare workers continue limiting treatment initiation of new patients on Ozempic and its other diabetic drug, Victoza, until the supply situation improves.
(Reporting by Shanima A in Bengaluru; Editing by Alex Richardson)
Comments